Antibody Drug Conjugates
Overview
LSCCB developed a series of Antibody Drug Conjugates (ADC) which show good long-term tumor suppression-effects in cancer models with minimal systemic toxicity.
Commercialisation opportunities
LSCCB, HKU and start-up company GoldPorp Pharma Ltd are developing the proprietary anticancer metal compounds with possibility of collaborative research projects and licensing.
Problem addressed
Traditional chemotherapy often affects both cancerous and healthy cells, leading to significant side effects. ADCs deliver cytotoxic drugs directly to cancer cells, sparing normal tissues and reducing side effects.
Innovation
- Our ADC is unique in employing clinically used tumor-targeting antibodies, advanced linkers, and novel cytotoxic payloads (LSCCB proprietary anticancer metal compounds and natural product derivatives)
Key impact
- Novel ADC payloads are being developed to overcome limitations such as inadequate efficacy and drug resistance associated with traditional payloads like tubulin inhibitors and DNA-damaging agents.
- Our ADCs with highly effective payloads developed in LSCCB have competitive advantages in the ADC drug development arena.
Application
- Investigational New Drug application in preparartion
Patent
- US Provisional Filing 63/598,041; 63/601,224; 63/636,226
Laboratory for Synthetic Chemistry and Chemical Biology (LSCCB) is an R&D centre funded by Health@InnoHK progamme of Innovation and Technology Commission of HKSAR. Established in 2020, LSCCB is operated with tripartite joint collaboration of The University of Hong Kong, Imperial College London and Peking University. LSCCB aims at integrating chemical and biomedical sciences to develop new molecular medicines and diagnostic tools for the treatment and analysis of human diseases, in particular, cancer. LSCCB currently assembles more than 20 principal investigators for 4 major research programmes including (a) Synthetic Chemistry; (b) Chemical Biology of Natural Products and Chinese Medicine; (c) Metal Anticancer Medicine, Diagnostics and Theranostics; and (d) Multi-Omics and Innovative Analytical Technologies for InnoHealth.
Enquiry
